Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723394 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 910
- Enrollment target
NCT04723394: Completed Phase 3 study, sponsored by AstraZeneca.
NCT04723394 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 910 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04723394, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 910 participants
- Enrollment target
Study Summary
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
Primary Outcome
Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, and lung infiltrates) or hypoxemia (SpO2 \< 90% in room air and/or severe respiratory distress) and a WHO Clinical Progression Scale score of 5 or higher.
Interventions
- DRUG Placebo
- DRUG AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 910 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 3 |
What the finished NCT04723394 record still lists
NCT04723394 is an interventional study that assigns participants to a tested intervention. The registered 910 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04723394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04723394 about?
NCT04723394 is a clinical study titled "Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults". This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
What is the current status of trial NCT04723394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 910 participants. The study started on 2021-01-28. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04723394?
The interventions under investigation include: Placebo (DRUG), AZD7442 (DRUG).
Who is sponsoring clinical trial NCT04723394?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04723394's enrollment target sits among peer trials
910 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI